MRK Merck & Company Inc
Company Analysis
Latest News
🔴 Merck is trading 3.86% down in after-hours trading — catalyst remains unclear
Merck is trading at $125.87, down -3.86% in after-hours trading, with no new August 10, 2026 company-specific announcement clearly explaining the decline. -...
Merck's second quarter revenue of $16.6B beat estimates, driven by strong Keytruda sales and an upgraded FY2026 outlook.
Merck reported second quarter 2026 revenue of $16.6 billion, a 5% year-over-year increase that surpassed analyst expectations. The company posted a non-GAAP...
Merck & Company Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Merck & Company is expected to report Q2 2026 revenue of $16.33 billion and a consensus EPS loss of $0.26, while the current $130.20 share price sits below the...
Merck Target Raised to $150 by Barclays Following Record Highs
Barclays raised its price target for Merck & Co. to $150 from $140. The firm maintained its Overweight rating on the stock. The revision follows a period of...
🟢 Merck is trading 3.1% up today as it rebounds amid a healthcare sector rally
Merck is trading at $134.78 (3.1% up) as it rebounds from an unexplained after-hours drop yesterday, gaining support from a broader move into healthcare...
🔴 Merck is trading 4.44% down today with no company-specific catalyst identified
Merck is trading at $124.96 (4.44% down) in after-hours trading following a regular-session close of $130.76, with no immediate company-specific news or...
Merck Inks Royalty-Free Deals for Experimental HIV Pill in 129 Countries
Merck & Co. signed seven non-exclusive, royalty-free voluntary licensing agreements with generic drug manufacturers. These agreements cover its experimental...
Merck Reportedly Among Bidders for Cancer Diagnostics Firm Personalis
Cancer diagnostics company Personalis (PSNL) explores a sale. The company received takeover interest from Merck (MRK) and at least two other bidders....
🟢 Merck is trading 3.1% up today after FDA approval of oral cholesterol drug Lipfendra
Merck is trading 3.1% up at $131.54 after winning FDA approval for Lipfendra, the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol in...
Merck Wins FDA Approval for Lipfendra, First Oral Cholesterol-Lowering Pill
The U.S. Food and Drug Administration approved Merck’s Lipfendra (enlicitide) for the treatment of hypercholesterolemia. This once-daily pill represents the...
🟢 Merck is trading 3.2% up today as UnitedHealth earnings lift healthcare sector
Merck is trading 3.2% up at $127.62 as a rally in healthcare stocks, sparked by strong UnitedHealth results, lifts the broader sector. • The XLV healthcare...
Merck to Unveil Phase 3 Data on Once-Weekly HIV Regimen at AIDS 2026
Merck will present new data from its HIV treatment and prevention pipeline. The company will present this data at the 26th International AIDS Conference (AIDS...
Merck Keytruda Beats Chemotherapy, Offering New Option for Endometrial Cancer
Merck’s Phase 3 KEYNOTE-C93 trial met its primary endpoint for the treatment of endometrial cancer. Keytruda monotherapy significantly improved...
Merck Secures EU Approval for Erbitux, Driving Wall Street Price Hikes
The European Commission approved Merck’s Erbitux on July 14, 2026. This regulatory green light covers Erbitux in combination with encorafenib and FOLFOX for...
Merck Secures FDA Breakthrough Status for Lupus Drug, Price Target Raised
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Merck’s enpatoran. This investigational oral TLR7/8 inhibitor treats...
Merck Hits 52-Week High, Boosted by Lung Cancer Drug Pipeline
Merck & Co. shares reached a new 12-month high of $130.29 on Wednesday. Bank of America raised its price target for the stock to $141 from $130. The firm also...
Merck faces US probe over China trials, citing military and IP risks
A bipartisan U.S. House committee launched a national security investigation into Merck & Co. regarding its clinical drug trials in China. The House Select...
Merck Wins FDA Approval for Keytruda-Trodelvy Combo, Cutting Cancer Risk 35%
The FDA approved Merck’s KEYTRUDA in combination with Gilead’s Trodelvy for advanced triple-negative breast cancer (TNBC). This approval applies to adult...
🟢 MRK is trading 3.2% up today on EU approval for Keytruda bladder cancer combo
MRK is trading 3.2% up at $124.40 after winning a key European regulatory approval for its oncology portfolio. • The European Commission cleared the...
Merck Secures EU Approval for Keytruda Combo, First-of-Its-Kind Bladder Cancer Treatment
The European Commission approved Merck’s anti-PD-1 therapy, Keytruda, in combination with Padcev. The regimen treats adult patients with resectable...